Hungary denies drug experiment claims

15 January 2001

Hungary's National Pharmaceutical Institute has denied that dangerousdrug experiments are being carried out on unsuspecting Hungarian patients.

The Institute was responding to US reports describing Hungary as a target for low-cost experimentation by US drugmakers on patients. One report, in the Washington Post, stated that US drug majors were conducting tests in Hungarian hospitals that would not be allowed under US law.

Janos Borvendeng, the Institute's deputy director, told a radio interview in Budapest that "allegations in this form are certainly not true." All clinical trials carried out in Hungary are regulated and have to be authorized by the Institute, as well as by an independent ethical committee, he said. The charge that US pharmaceutical manufacturers were taking advantage of the relaxed attitude of the Hungarian authorities was "ill-willed," he said, adding that there was no need for official sanction to conduct tests in Belgium, the Netherlands or Switzerland.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight